Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report

Moisés A. Calderon; Susan Waserman; David I. Bernstein; Pascal Demoly; Jo Douglass; Remi Gagnon; Constance H. Katelaris; Harold Kim; Harold S. Nelson; Yoshitaka Okamoto; Kimihiro Okubo; J. Christian Virchow; Lawrence DuBuske; Thomas B. Casale; G. Walter Canonica; Hendrik Nolte

doi:10.1016/j.jaip.2020.04.071

Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report

Moisés A. Calderon, Susan Waserman, David I. Bernstein, Pascal Demoly, Jo Douglass, Remi Gagnon, Constance H. Katelaris, Harold Kim, Harold S. Nelson, Yoshitaka Okamoto, Kimihiro Okubo, J. Christian Virchow, Lawrence DuBuske, Thomas B. Casale, G. Walter Canonica, Hendrik Nolte

Western Sydney University

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.

Original language	English
Pages (from-to)	2920-2936
Number of pages	17
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	9
DOIs	https://doi.org/10.1016/j.jaip.2020.04.071
Publication status	Published - 2020

Keywords

allergy
asthma
hay fever
immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaip.2020.04.071

Cite this

Calderon, M. A., Waserman, S., Bernstein, D. I., Demoly, P., Douglass, J., Gagnon, R., Katelaris, C. H., Kim, H., Nelson, H. S., Okamoto, Y., Okubo, K., Virchow, J. C., DuBuske, L., Casale, T. B., Canonica, G. W., & Nolte, H. (2020). Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report. Journal of Allergy and Clinical Immunology: In Practice, 8(9), 2920-2936. https://doi.org/10.1016/j.jaip.2020.04.071

@article{4258d3d02f9d4af2ad93a549785935b9,

title = "Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report",

abstract = "Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.",

keywords = "allergy, asthma, hay fever, immunotherapy",

author = "Calderon, {Mois{\'e}s A.} and Susan Waserman and Bernstein, {David I.} and Pascal Demoly and Jo Douglass and Remi Gagnon and Katelaris, {Constance H.} and Harold Kim and Nelson, {Harold S.} and Yoshitaka Okamoto and Kimihiro Okubo and Virchow, {J. Christian} and Lawrence DuBuske and Casale, {Thomas B.} and Canonica, {G. Walter} and Hendrik Nolte",

year = "2020",

doi = "10.1016/j.jaip.2020.04.071",

language = "English",

volume = "8",

pages = "2920--2936",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "9",

}

Calderon, MA, Waserman, S, Bernstein, DI, Demoly, P, Douglass, J, Gagnon, R, Katelaris, CH, Kim, H, Nelson, HS, Okamoto, Y, Okubo, K, Virchow, JC, DuBuske, L, Casale, TB, Canonica, GW & Nolte, H 2020, 'Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report', Journal of Allergy and Clinical Immunology: In Practice, vol. 8, no. 9, pp. 2920-2936. https://doi.org/10.1016/j.jaip.2020.04.071

TY - JOUR

T1 - Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report

AU - Calderon, Moisés A.

AU - Waserman, Susan

AU - Bernstein, David I.

AU - Demoly, Pascal

AU - Douglass, Jo

AU - Gagnon, Remi

AU - Katelaris, Constance H.

AU - Kim, Harold

AU - Nelson, Harold S.

AU - Okamoto, Yoshitaka

AU - Okubo, Kimihiro

AU - Virchow, J. Christian

AU - DuBuske, Lawrence

AU - Casale, Thomas B.

AU - Canonica, G. Walter

AU - Nolte, Hendrik

PY - 2020

Y1 - 2020

N2 - Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.

AB - Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.

KW - allergy

KW - asthma

KW - hay fever

KW - immunotherapy

UR - https://hdl.handle.net/1959.7/uws:57603

U2 - 10.1016/j.jaip.2020.04.071

DO - 10.1016/j.jaip.2020.04.071

M3 - Article

SN - 2213-2198

VL - 8

SP - 2920

EP - 2936

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 9

ER -

Clinical practice of allergen immunotherapy for allergic rhinoconjunctivitis and asthma : an expert panel report

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this